Connecticut Secures $8 Million Mylan Settlement

The state reached an antitrust agreement that includes 10,000 free EpiPens for local health centers.

Updated on Oct. 22, 2026 in Allergies

Isometric editorial illustration showing an auto-injector device on a flat surface, symbolizing the state settlement and health equipment provision. — Connecticut has reached an $8 million antitrust settlement with Mylan to resolve allegations of anticompetitive practices regarding the pricing of allergy medications. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies face stricter penalties for significant price hikes on life-saving medications?

Connecticut has finalized an $8 million settlement with pharmaceutical company Mylan to resolve allegations of antitrust violations. As part of the agreement, Mylan will also provide 10,000 free EpiPens for distribution across the state.

Why it matters

The settlement addresses claims that Mylan engaged in anticompetitive behavior to stall the market entry of lower-cost generic alternatives. These legal actions follow a period of intense public scrutiny regarding significant price hikes for life-saving allergy medication.

The settlement includes $8 million in funds and 5,000 two-packs of EpiPens. These supplies are currently being distributed to 30 Federally Qualified Health Centers across Connecticut.

The players

Mylan

This pharmaceutical company is a global manufacturer of generic and specialty medicines.

Connecticut Department of Public Health

This state agency is responsible for overseeing public health initiatives and health care facility standards in Connecticut.

The details

Mylan allegedly violated state antitrust and consumer protection laws by entering into agreements to delay the release of generic competitors. While the company denies all allegations of wrongdoing, the agreement provides relief to residents who utilize state-funded health facilities.

In 2016, Mylan increased EpiPen prices by 400 percent.
On October 22, 2026, the Connecticut Attorney General announced the settlement.

Health Landscape

This settlement reflects ongoing regulatory efforts to ensure market competition and affordability for critical medical supplies like the Sherman Antitrust Act intends. It marks a shift from historical pricing controversies toward state-level legal enforcement against pharmaceutical market barriers.

Residents who rely on Federally Qualified Health Centers for allergy management will gain improved access to emergency medication. This distribution directly offsets the financial burden caused by previous price increases for essential treatments.

The takeaway

This agreement ensures that critical medication remains accessible through the states safety-net clinics. Patients should verify with their local Federally Qualified Health Center to see if they qualify for the newly available supplies.